My­ovant’s re­l­u­golix wins a piv­otal prostate can­cer show­down with an old stan­dard — com­ing down to the wire on ap­provals

My­ovant $MY­OV has round­ed the fi­nal turn in its de­vel­op­ment race to get re­l­u­golix down to the reg­u­la­to­ry wire at the FDA. And the biotech joined the vir­tu­al crowd at AS­CO with the kind of da­ta need­ed to keep the in­vestor crowd’s at­ten­tion.

Much of the at­ten­tion on the drug has been fo­cused on uter­ine fi­broids, where Ab­b­Vie just scored a reg­u­la­to­ry win for their ri­val drug Ori­ahnn (elagolix) as the biotech post­ed re­sults in prostate can­cer at the AS­CO meet­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER